Press coverage about Curis (NASDAQ:CRIS) has been trending somewhat positive on Tuesday, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Curis earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.24143922853 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of equities research analysts have weighed in on the company. BidaskClub downgraded Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. ValuEngine raised Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Curis in a report on Friday, May 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $5.88.

Curis (NASDAQ CRIS) opened at 1.71 on Tuesday. Curis has a one year low of $1.60 and a one year high of $3.72. The firm’s market capitalization is $245.85 million. The stock has a 50 day moving average price of $1.98 and a 200 day moving average price of $2.32.

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The business had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. On average, equities analysts predict that Curis will post ($0.40) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Curis (NASDAQ:CRIS) Receiving Somewhat Favorable News Coverage, Accern Reports” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Insider Buying and Selling by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with's FREE daily email newsletter.